AI assistant
Sending…
Ovid Therapeutics Inc. — Director's Dealing 2025
Jun 18, 2025
34195_dirs_2025-06-18_8103984f-3c5b-4583-a7df-673d71ac1e6a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Ovid Therapeutics Inc. (OVID)
CIK: 0001636651
Period of Report: 2025-02-20
Reporting Person: Fitzgerald Kevin Joseph (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-20 | Stock Option (right to buy) | $0.57 | A | 45000 | Acquired | 2035-02-19 | Common Stock (45000) | Direct |
Footnotes
F1: The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.
More from Ovid Therapeutics Inc.
Board/Management Information
2026
Jun 3
Interim / Quarterly Report
2026
May 12
Report Publication Announcement
2026
May 12
Annual Report
2026
Apr 27
Proxy Solicitation & Information Statement
2026
Apr 27
Capital/Financing Update
2026
Apr 27
Capital/Financing Update
2026
Apr 20
Director's Dealing
2026
Mar 26
Annual Report
2026
Mar 18
Director's Dealing
2026
Mar 2